Our Mission:Develop tumor-penetrating drugs to benefit cancer patients

PDC is next-gen XDC modality; Rapidly developing 5 oncology pipelines,  indication in specialist; Clinical data read-out in 2024; Novel smaller drug conjugates, including peptide-drug conjugates (PDCs) and nanobody-drug conjugates (NDCs)

About Conjustar

Tianjin Conjustar Biologics Co., Ltd. is located in Tianjin Airport Free Trade Zone, was founded on February 21, 2022, by the Fosun Health Capital and Wuxi Apptec jointly incubated, the seed round financing amount of 45.5 million yuan.

Conjustar is committed to developing new miniaturized coupling drugs (polypeptide/nanoantibody coupling drugs, PDC/NDC) to cure solid tumors.

History

◆ In November, angel round of financing of 55 million RMB was obtained
 

◆ In August, the Zhangjiang office of Conjustar was put into use
 

◆ In March, 45.5 million RMB was obtained in seed funding
 

◆ In February, Tianjin Conjustar Biologics Co., Ltd. was registered and established in Tianjin